BBIO Presents Trial Results
BridgeBio presents primary results from Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BridgeBio presents primary results from Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia